Connection
Connie Valdez to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Connie Valdez has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.749 |
|
|
|
-
Champion M, Wills Avila G, Garcia AE, ?lvarez Delgado FM, Valdez CA. Impact of Initiating a GLP1 Agonist and/or SGLT2 Inhibitor Therapy on De-Escalation and Discontinuation of Insulin and Diabetes Control When Managed by an Interprofessional Collaborative Team. J Prim Care Community Health. 2024 Jan-Dec; 15:21501319241231398.
Score: 0.320
-
Dumont C, Fitzgerald L, Valdez CA. Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting. J Prim Care Community Health. 2020 Jan-Dec; 11:2150132720973827.
Score: 0.242
-
Valdez CA. New agents in the management of type 2 diabetes: do they provide an opportunity for a shift in the treatment paradigm? J Manag Care Pharm. 2008 Sep; 14(7):650-4.
Score: 0.110
-
Nguyen KV, Weidner JA, Shaw KF, Valdez CA. Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery. Am J Health Syst Pharm. 2016 Mar 01; 73(5):292-7.
Score: 0.046
-
LaMarr B, Valdez C, Driscoll K, Ryan M. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. Am J Health Syst Pharm. 2010 Feb 15; 67(4):290-4.
Score: 0.031